Cargando…
Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor
Semaphorin 4D (Sema4D) is a neurotrophin that is secreted by osteoclasts and binds to its receptor PlexinB1 on osteoblasts to inhibit their differentiation and function. Adenosine A2A activation inhibits osteoclast Sema4D-mediated secretion, diminishes inflammatory osteolysis and prevents bone loss...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583797/ https://www.ncbi.nlm.nih.gov/pubmed/34768920 http://dx.doi.org/10.3390/ijms222111490 |
_version_ | 1784597290272423936 |
---|---|
author | Llamas-Granda, Patricia Martin-Rodríguez, Laura Largo, Raquel Herrero-Beaumont, Gabriel Mediero, Aránzazu |
author_facet | Llamas-Granda, Patricia Martin-Rodríguez, Laura Largo, Raquel Herrero-Beaumont, Gabriel Mediero, Aránzazu |
author_sort | Llamas-Granda, Patricia |
collection | PubMed |
description | Semaphorin 4D (Sema4D) is a neurotrophin that is secreted by osteoclasts and binds to its receptor PlexinB1 on osteoblasts to inhibit their differentiation and function. Adenosine A2A activation inhibits osteoclast Sema4D-mediated secretion, diminishes inflammatory osteolysis and prevents bone loss following tenofovir (one of the most used antivirals in HIV). Therefore, tenofovir might activate Sema4D signaling to alter bone turnover. Female C57Bl/6/A2AKO mice were ovariectomized and treated with saline (control), tenofovir 75 mg/Kg/day, dipyridamole 25 mg/Kg/day or a combination for 5 weeks and long bones were prepared for histology. Primary murine-induced osteoclast/osteoblast were challenged with tenofovir/dipyridamole 1 μM each, and the expression of Sema4D/PlexinB1, RhoA/ROCK/IGF1R was studied by RT-PCR, Western blot and immunostaining. In vivo tenofovir showed an increased expression of Sema4D when compared to control mice, and dipyridamole reverted the expression in an A2A-dependent manner. In vitro, tenofovir increases Sema4D expression and secretion in osteoclast precursors, and pre-treatment with dipyridamole reverted this effect. pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner. This suggests that tenofovir increases bone loss by activation of Sema4D/PlexinB1 signaling, which inhibits osteoblast differentiation. Agents that increase local adenosine concentrations, such as dipyridamole, might prevent bone loss following the inhibition of this pathway. |
format | Online Article Text |
id | pubmed-8583797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85837972021-11-12 Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor Llamas-Granda, Patricia Martin-Rodríguez, Laura Largo, Raquel Herrero-Beaumont, Gabriel Mediero, Aránzazu Int J Mol Sci Article Semaphorin 4D (Sema4D) is a neurotrophin that is secreted by osteoclasts and binds to its receptor PlexinB1 on osteoblasts to inhibit their differentiation and function. Adenosine A2A activation inhibits osteoclast Sema4D-mediated secretion, diminishes inflammatory osteolysis and prevents bone loss following tenofovir (one of the most used antivirals in HIV). Therefore, tenofovir might activate Sema4D signaling to alter bone turnover. Female C57Bl/6/A2AKO mice were ovariectomized and treated with saline (control), tenofovir 75 mg/Kg/day, dipyridamole 25 mg/Kg/day or a combination for 5 weeks and long bones were prepared for histology. Primary murine-induced osteoclast/osteoblast were challenged with tenofovir/dipyridamole 1 μM each, and the expression of Sema4D/PlexinB1, RhoA/ROCK/IGF1R was studied by RT-PCR, Western blot and immunostaining. In vivo tenofovir showed an increased expression of Sema4D when compared to control mice, and dipyridamole reverted the expression in an A2A-dependent manner. In vitro, tenofovir increases Sema4D expression and secretion in osteoclast precursors, and pre-treatment with dipyridamole reverted this effect. pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner. This suggests that tenofovir increases bone loss by activation of Sema4D/PlexinB1 signaling, which inhibits osteoblast differentiation. Agents that increase local adenosine concentrations, such as dipyridamole, might prevent bone loss following the inhibition of this pathway. MDPI 2021-10-25 /pmc/articles/PMC8583797/ /pubmed/34768920 http://dx.doi.org/10.3390/ijms222111490 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Llamas-Granda, Patricia Martin-Rodríguez, Laura Largo, Raquel Herrero-Beaumont, Gabriel Mediero, Aránzazu Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor |
title | Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor |
title_full | Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor |
title_fullStr | Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor |
title_full_unstemmed | Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor |
title_short | Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor |
title_sort | tenofovir modulates semaphorin 4d signaling and regulates bone homeostasis, which can be counteracted by dipyridamole and adenosine a2a receptor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583797/ https://www.ncbi.nlm.nih.gov/pubmed/34768920 http://dx.doi.org/10.3390/ijms222111490 |
work_keys_str_mv | AT llamasgrandapatricia tenofovirmodulatessemaphorin4dsignalingandregulatesbonehomeostasiswhichcanbecounteractedbydipyridamoleandadenosinea2areceptor AT martinrodriguezlaura tenofovirmodulatessemaphorin4dsignalingandregulatesbonehomeostasiswhichcanbecounteractedbydipyridamoleandadenosinea2areceptor AT largoraquel tenofovirmodulatessemaphorin4dsignalingandregulatesbonehomeostasiswhichcanbecounteractedbydipyridamoleandadenosinea2areceptor AT herrerobeaumontgabriel tenofovirmodulatessemaphorin4dsignalingandregulatesbonehomeostasiswhichcanbecounteractedbydipyridamoleandadenosinea2areceptor AT medieroaranzazu tenofovirmodulatessemaphorin4dsignalingandregulatesbonehomeostasiswhichcanbecounteractedbydipyridamoleandadenosinea2areceptor |